MedTrace Logo

"Prevention of Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients"

NCT05189535 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2024-01-23

No results posted yet for this study

Summary

The aim of this study is to evaluate the effect of pentoxifylline 400 mg twice daily administration on the prevention of paclitaxel-Induced peripheral neuropathy in breast cancer patients.

Conditions

Interventions

DRUG

Pentoxifylline

Pentoxifylline 400 mg oral tablet twice daily for 12 weeks.

DRUG

Paclitaxel

Paclitaxel I.V 80 mg/m2 weekly

DRUG

Placebo

placebo

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-03
Primary Completion
2023-09-18
Completion
2023-09-28

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05189535 on ClinicalTrials.gov